Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Denosumab CP4 vs CP2 in Healthy Volunteers
NCT02053753Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2014
- Primary completion
- Aug 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of denosumab in bone metastases, Giant Cell Tumor of Bone (GCTB), multiple myeloma (MM) and 1 more (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Drug Concentration at 127 days and Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose. Started Feb 2014; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasesGiant Cell Tumor of Bone (GCTB)multiple myeloma (MM)hypercalcemia of malignancy (HCM)
Beyond the preview
Go deeper on NCT02053753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053753.